CONFERENCEProject title: Biomimetic MXene Nanoplatforms for Targeted Combination Therapy of Triple-Negative Breast Cancer (BioMIX)
Project contract number:
Project implementation time: 01.11.2026-30.09.2030
Total project funding: 1 147 740 EUR
University of Latvia funding: 155 100 EUR
Project research coordinator: Dr. Volodymyr Deineka (Advanced Biomaterials and Biophysics Laboratory)
Project Manager: Inga Šīrante, FST project manager
Projekt Consortium
Co-ordinator: University of Latvia
Beneficiaries:
Ankara University, Ankara, Turkey
University of Padua, Padua, Italy
Adam Mickiewicz University, Poznan, Poland
CSD Health Care (CSD Lab), Kyiv, Ukraine
MB SENSOGRAFA, Vilnius, Lithuania
Materials Research Centre, Kyiv, Ukraine
National Institute of Health and Medical Research, Paris, France
Yoursciencebe, Brussels, Belgium
BIOFABICS LDA, Porto, Portugal
University of Liverpool, Liverpool, United Kingdom
Associated partners:
Auckland University of technology, Auckland, New Zealand
Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
Summary:
Triple-Negative Breast Cancer (TNBC) remains one of the most challenging subtypes of oncology due to its high metastatic potential, lack of targeted receptors, and rapid development of drug resistance. The BioMIX project proposes a disruptive solution: a "stealth" biomimetic nanoplatform designed to bypass the immune system and deliver a potent combination of chemotherapy, gene therapy, and sonodynamic therapy (SDT) directly to the tumor site. The core of the BioMIX technology is a two-dimensional Ti3C2 MXene nanosheet, which serves as a structural scaffold and a high efficiency sonosensitiser. This core is functionalized with a pH-responsive polydopamine shell to entrap Doxorubicin and a cationic layer to complex anti-MDR1 siRNA. To achieve superior targeting, the construct is ‘camouflaged’ with a hybrid membrane fused from TNBC cells and macrophages, further enhanced with iRGD peptides for deep-tissue penetration. Upon reaching the tumor, low-intensity ultrasound is applied to trigger localised hyperthermia and reactive oxygen species (ROS) generation, causing controlled drug release and inducing targeted cancer cell apoptosis.
As an MSCA Staff Exchange action, BioMIX is built on a highly interdisciplinary consortium of 13 international partners across the academic and industrial sectors. The project is structured to facilitate more than 200 person-months of knowledge transfer, conveying critical expertise in 2D materials science, microfluidic manufacturing, and preclinical oncology research. By integrating "Tumor-on-a-Chip" validation and in vivo efficacy studies, BioMIX aims to establish a clinically translatable framework for targeted nanomedicine while reducing the systemic side effects (such as cardiotoxicity) of conventional chemotherapy. The project’s outcomes will strengthen European leadership in nanobiotechnology and provide a scalable framework for the next generation of biomimetic therapeutic vehicles aligned with Europe’s Beating Cancer Plan.
More about the project